Subantimicrobial Doxycycline in Acne

• Status: Completed
• Trial end date: 2021-11-08
• Target enrollment: 0
• Participant gender: All

Summary

Antibiotic resistance is a public health problem that worsens the more we prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, we can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. We aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Michigan State University
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Documented moderate to severe facial acne

Exclusion Criteria:

• Other skin conditions on the face

• Previous antibiotic treatment for acne

• Use of antibiotics for any reason within the past month

• Use of new prescription regiment for acne within the last 3 months

• Positive pregnancy test in the clinic

• Cognitive impairments